Table 1 Patient baseline characteristics (n = 16)
From: Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Characteristic | N (%) |
|---|---|
Median age, years (range) | 48 (31–78) |
Sex | |
 Female | 8 (50) |
 Male | 8 (50) |
Race | |
 Caucasian | 12 (75) |
 Other | 4 (25) |
ECOG performance status | |
 0 | 3 (19) |
 1 | 13 (81) |
Hormonally functioning tumor | |
 Yes | 10 (63) |
 No | 6 (38) |
Median number of prior therapies (range) | 2 (1–5) |